Evolution of hepatic fibrosis research

Hepatology Research

Volumn 41, Issue 3, 2011, Pages 199-208

  Kawada, Norifumi ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Collagen; Cytokine; Growth factor; Stellate cell; Transient elastography

Indexed keywords

ADEFOVIR; COLLAGEN; COLLAGEN TYPE 4; ENTECAVIR; FARGLITAZAR; HYALURONIC ACID; INTERLEUKIN 6; LAMIVUDINE; MATRIX METALLOPROTEINASE; NATURAL KILLER CELL RECEPTOR NKG2D; PEGINTERFERON; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; REACTIVE OXYGEN METABOLITE; RIBAVIRIN; SCATTER FACTOR; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ACOUSTIC RADIATION FORCE IMPULSE; CANCER SCREENING; DIAGNOSTIC PROCEDURE; ECHOGRAPHY; ELASTOGRAPHY; EXTRACELLULAR MATRIX; FIBROGENESIS; HEPATITIS B; HEPATITIS C; HUMAN; INNATE IMMUNITY; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FIBROSIS; NATURAL KILLER CELL; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PRIORITY JOURNAL; REAL TIME TISSUE ELASTOGRAPHY; REVIEW; STELLATE CELL; TRANSIENT ELASTOGRAPHY; VIRUS HEPATITIS;

EID: 79951803916     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00776.x     Document Type: Review

References (51)

1. Friedman SL, Roll FJ, Boyles J, Bissell DM. Hepatic lipocytes: the principal collagen-producing cells of normal rat liver. Proc Natl Acad Sci USA 1985; 82: 8681-5.
2. Friedman SL. Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol 2010; 7: 425-36.
3. Villanueva A, Minguez B, Forner A, Reig M, Llovet JM. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med 2010; 61: 317-28.
4. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51: 1820-32.
5. Gane EJ, Roberts SK, Stedman CA etal. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010; 376: 1467-75.
6. Wake K. Perisinusoidal stellate cells (fat-storing cells, interstitial cells, lipocytes), their related structure in and around the liver sinusoids, and vitamin A-storing cells in extrahepatic organs. Int Rev Cytol 1980; 66: 303-53.
7. Kawada N, Tran-Thi TA, Klein H, Decker K. The contraction of hepatic stellate (Ito) cells stimulated with vasoactive substances. Possible involvement of endothelin 1 and nitric oxide in the regulation of the sinusoidal tonus. Eur J Biochem 1993; 213: 815-23.
8. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008; 88: 125-72.
9. Mann DA, Marra F. Fibrogenic signalling in hepatic stellate cells. J Hepatol 2010; 52: 949-50.
10. Choi SS, Syn WK, Karaca GF etal. Leptin promotes the myofibroblastic phenotype in hepatic stellate cells by activating the hedgehog pathway. J Biol Chem 2010; 285: 36551-60.
11. Forbes SJ, Russo FP, Rey V etal. A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. Gastroenterology 2004; 126: 955-63.
12. Kisseleva T, Uchinami H, Feirt N etal. Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. J Hepatol 2006; 45: 429-38.
13. Dranoff JA, Wells RG. Portal fibroblasts: underappreciated mediators of biliary fibrosis. Hepatology 2010; 51: 1438-44.
14. Zeisberg M, Yang C, Martino M etal. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem 2007; 282: 23337-47.
15. Scholten D, Osterreicher CH, Scholten A etal. Genetic labeling does not detect epithelial-to-mesenchymal transition of cholangiocytes in liver fibrosis in mice. Gastroenterology 2010; 139: 987-98.
16. Taura K, Miura K, Iwaisako K etal. Hepatocytes do not undergo epithelial-mesenchymal transition in liver fibrosis in mice. Hepatology 2010; 51: 1027-36.
17. Jiang JX, Venugopal S, Serizawa N etal. Reduced nicotinamide adenine dinucleotide phosphate oxidase 2 plays a key role in stellate cell activation and liver fibrogenesis in vivo. Gastroenterology 2010; 139: 1375-84.
18. Kim SY, Cho BH, Kim UH. CD38-mediated Ca2+ signaling contributes to angiotensin II-induced activation of hepatic stellate cells: attenuation of hepatic fibrosis by CD38 ablation. J Biol Chem 2010; 285: 576-82.
19. Seki E, De Minicis S, Osterreicher CH etal. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007; 13: 1324-32.
20. Syn WK, Choi SS, Liaskou E etal. Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. Hepatology 2011; 53: 106-15.
21. Sahin H, Trautwein C, Wasmuth HE. Functional role of chemokines in liver disease models. Nat Rev Gastroenterol Hepatol 2010; 7: 682-90.
22. Syn WK, Oo YH, Pereira TA etal. Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease. Hepatology 2010; 51: 1998-2007.
23. Hézode C, Zafrani ES, Roudot-Thoraval F etal. Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C. Gastroenterology 2008; 134: 432-9.
24. Mallat A, Lotersztajn S. Cannabinoid receptors as novel therapeutic targets for the management of non-alcoholic steatohepatitis. Diabetes Metab 2008; 34: 680-4.
25. Mann J, Chu DC, Maxwell A etal. MeCP2 controls an epigenetic pathway that promotes myofibroblasttransdifferentiation and fibrosis. Gastroenterology 2010; 138: 705-14.
26. Ogawa T, Iizuka M, Sekiya Y etal. Suppression of type I collagen production by microRNA-29b in cultured human stellate cells. Biochem Biophys Res Commun 2010; 391: 316-21.
27. Roderburg C, Urban GW, Bettermann K etal. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology 2011; 53: 209-18.
28. Hold GL, Untiveros P, Saunders KA etal. Role of host genetics in fibrosis. Fibrogenesis Tissue Repair 2009; 2: 6.
29. Huang H, Shiffman ML, Friedman S etal. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology 2007; 46: 297-306.
30. Guo J, Hong F, Loke J etal. A DDX5 S480A polymorphism is associated with increased transcription of fibrogenic genes in hepatic stellate cells. J Biol Chem 2010; 285: 5428-37.
31. Sawitza I, Kordes C, Reister S, Häussinger D. The niche of stellate cells within rat liver. Hepatology 2009; 50: 1617-24.
32. She H, Xiong S, Hazra S etal. Adipogenic transcriptional regulation of hepatic stellate cells. J Biol Chem 2005; 280: 4959-67.
33. Gawrieh S, Papouchado BG, Burgart LJ etal. Early hepatic stellate cell activation predicts severe hepatitis C recurrence after liver transplantation. Liver Transpl 2005; 11: 1207-13.
34. Benyon RC, Arthur MJ. Extracellular matrix degradation and the role of hepatic stellate cells. Semin Liver Dis 2001; 21: 373-84.
35. Kornek M, Popov Y, Libermann TA, Afdhal NH, Schuppan D. Human T cell microparticles circulate in blood of hepatitis patients and induce fibrolytic activation of hepatic stellate cells. Hepatology 2011; 53: 230-42.
36. Inagaki Y, Nemoto T, Kushida M etal. Interferon alfa down-regulates collagen gene transcription and suppresses experimental hepatic fibrosis in mice. Hepatology 2003; 38: 890-9.
37. Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010; 29: 4989-500.
38. Wang Y, Gao J, Zhang D, Zhang J, Ma J, Jiang H. New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis. J Hepatol 2010; 53: 132-44.
39. Mejias M, Garcia-Pras E, Tiani C, Miquel R, Bosch J, Fernandez M. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 2009; 49: 1245-56.
40. Pinzani M, Vizzutti F, Arena U, Marra F. Technology Insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography. Nat Clin Pract Gastroenterol Hepatol 2008; 5: 95-106.
41. Guha IN, Parkes J, Roderick P etal. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008; 47: 455-60.
42. Ngo Y, Munteanu M, Messous D etal. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem 2006; 52: 1887-96.
43. Parkes J, Roderick P, Harris S etal. Enhanced Liver Fibrosis (ELF) Test can predict clinical outcomes in patients with mixed aetiology chronic liver disease. Gut 2010; 59: 1245-51.
44. Castéra L, Vergniol J, Foucher J etal. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-50.
45. Wong VW, Vergniol J, Wong GL etal. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010; 51: 454-62.
46. Dechêne A, Sowa JP, Gieseler RK etal. Acute liver failure is associated with elevated liver stiffness and hepatic stellate cell activation. Hepatology 2010; 52: 1008-16.
47. Friedrich-Rust M, Ong MF, Herrmann E etal. Real-time elastography for noninvasive assessment of liver fibrosis in chronic viral hepatitis. AJR Am J Roentgenol 2007; 188: 758-64.
48. Morikawa H, Fukuda K, Kobayashi S etal. Real-time tissue elastography as a tool for the noninvasive assessment of liver stiffness in patients with chronic hepatitis C. J Gastroenterol 2010; Aug 10. [Epub ahead of print]
49. Yoneda M, Suzuki K, Kato S etal. Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography. Radiology 2010; 256: 640-7.
50. Castéra L, Foucher J, Bernard PH etal. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13, 369 examinations. Hepatology 2010; 51: 828-35.
51. Masuzaki R, Tateishi R, Yoshida H etal. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology 2009; 49: 1954-61.